Clinicians frequently encounter the challenge of concomitant lung cancer surgery in patients with existing cardiovascular diseases (CVDs). These conditions often coexist because of shared risk factors like advanced age and chronic inflammation. Managing this complex population requires an integrated, multidisciplinary approach to balance oncologic urgency with cardiac stability. Furthermore, advancements in surgical techniques have significantly expanded the therapeutic window for these high-risk individuals.

Optimizing Outcomes in Concomitant Lung Cancer Surgery

Preoperative risk assessment is essential for successful outcomes. Specifically, Japanese, American, and European societies emphasize tailored sequencing for cardiac and oncologic interventions. Generally, a staged approach is the standard of care. This involves initial cardiac stabilization, followed by pulmonary resection after a recovery period. However, simultaneous surgery, such as off-pump coronary artery bypass grafting (OPCAB) combined with lung resection, is feasible in carefully selected patients. In addition, surgeons now utilize minimally invasive options like segmentectomy to preserve lung function in frail patients.

Modern treatments also introduce new complexities. For instance, the cardiac toxicity of immune checkpoint inhibitors (ICIs) and EGFR-TKIs must be evaluated during neoadjuvant planning. These therapies can increase the risk of myocarditis or pericardial disorders. Consequently, integrating cardiovascular expertise into the thoracic oncology team is vital for patient safety. Early identification of cardiovascular risks ensures that surgical candidates receive the most appropriate care sequence.

Frequently Asked Questions

What is the preferred sequencing for cardiac and oncologic interventions?

Most guidelines recommend a staged approach, where clinicians first stabilize the heart before proceeding to lung resection. This reduces the risk of perioperative cardiac events.

Are minimally invasive surgeries safe for frail patients with CVD?

Yes, techniques like video-assisted segmentectomy or parenchymal-sparing surgery help reduce surgical trauma. These options are particularly beneficial for elderly or medically complex patients.

How do modern immunotherapies impact surgical planning?

Immunotherapies can cause rare but severe cardiotoxicity. Surgeons must monitor patients for myocarditis and other complications, especially if the patient has a history of coronary artery disease.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Kanzaki R et al. Surgical management of concomitant lung cancer and cardiovascular diseases: a multidisciplinary perspective. Lung Cancer Manag. 2026 Dec undefined. doi: 10.1080/17581966.2026.2654371. PMID: 41945887.

Tourmousoglou CE, et al. Simultaneous occurrence of coronary artery disease and lung cancer: what is the best surgical treatment strategy? Interact Cardiovasc Thorac Surg. 2014;19(4):673-681.

Yamani N, et al. Immune checkpoint inhibitor-induced cardiotoxicity in patients with lung cancer: a systematic review and meta-analysis. Cardio-Oncology. 2024;10(1):35.